Adherence with tobramycin inhaled solution and health care utilization

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Briesacher, Becky A ^a   Quittner, Alexandra L ^b   Saiman, Lisa ^c   Sacco, Patricia ^d   Fouayzi, Hassan ^e   Quittell, Lynne M ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Department of Biology   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMORBIDITY; CYSTIC FIBROSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; ECONOMICS; HEALTH SERVICE; ISOLATION AND PURIFICATION; PSEUDOMONAS INFECTION; UTILIZATION REVIEW;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; FEMALE; HEALTH SERVICES; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; YOUNG ADULT;

EID: 78651536177     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-5     Document Type: Article

References (26)

1. Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2007. 2008, Bethesda, MD, Cystic Fibrosis Foundation.
2. Accurso FJ. Pulmonary and Critical Care Updates: Update in Cystic Fibrosis 2007. Am J Respir Crit Care Med 2008, 177:1058-1061. 10.1164/rccm.200801-069UP, 2720148, 18460460.
3. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006, 5:177-185. 10.1016/j.jcf.2006.03.002, 16679071.
4. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004, 42:200-209. 10.1097/01.mlr.0000114908.90348.f9, 15076819.
5. Quittner AL, Barker DH, Marciel KK, Grimley ME. Cystic fibrosis: A model for drug discovery and patient care 2009, NY: Guilford Press, 4.
6. Cystic Fibrosis Foundation Patients Registry: 2005 Annual Data Report. 2006, Bethesda, MD: Cystic Fibrosis Foundation, Cystic Fibrosis Foundation.
7. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100. 10.1002/ppul.10127, 12112774.
8. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138:699-704. 10.1067/mpd.2001.112897, 11343046.
9. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176:957-969. 10.1164/rccm.200705-664OC, 17761616.
10. Zindani G, Streetman D, Streetman D, Nasr S. Adherence to treatment in children and adolescent patiens with cystic fibrosis. J Adolesc Health 2006, 38:13-17. 10.1016/j.jadohealth.2004.09.013, 16387243.
11. Suri R, Wallis C, Bush A, et al. A comparitive study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technol Assess 2002, 6:1-60.
12. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007, 132:562-568. 10.1378/chest.06-2888, 17646236.
13. Moskowitz S, Silva S, Mayer-Hamblett N, Pasta D, Mink D, Wagener S, Kostan M, Morgan W. Inhaled Antibiotic Use Among North American Cystic Fibrosis Patients. Annual Meeting of American Thorasic Society 2007,
14. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004, 125:1S-39S. 10.1378/chest.125.1_suppl.1S, 14734689.
15. Adamson D, Chang S, Hansen L. Health research data for the real world: The MarketScan databases, in White Paper 2005, Ann Arbor, MI: Thomson Medstat.
16. MarketScan Research Databases User Guide and Database Dictionary. 2006, Ann Arbor, MI: Thomson Medstat.
17. Rector TS, Wickstrom SL, Shah M, Thomas Greeenlee N, Rheault P, Rogowski J, Freedman V, Adams J, Escarce JJ. Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res 2004, 39:1839-1857. 10.1111/j.1475-6773.2004.00321.x, 1361101, 15533190.
18. Consumer Price Indexes. , http://www.bls.gov/cpi/
19. Ash A, Ellis RP, Pope G, Ayanian J, Bates D, Burstin H, Iezzoni L, McKay E, Yu W. Using Diagnoses to Describe Populations and Predict Costs. Health Care Financ Rev 2000, 21:7-28.
20. Petersen LA, Pietz K, Woodard LD, Byrne M. Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes. Med Care 2005, 43:61-67.
21. Briesacher BA, Sacco P, Fouayzi H, Quittner A. Tobramycin inhaled solution utilization in cystic fibrosis patients in a privately insured US population. 2009, Toronto.
22. Cystic Fibrosis Foundation Patient Registry 2001 and 2006 Annual Data Report. 2007, Bethesda, MA, Cystic Fibrosis Foundation.
23. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology 2008, 43:874-881. 10.1002/ppul.20873, 18668689.
24. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30. 10.1056/NEJM199901073400104, 9878641.
25. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999, 37:846-857. 10.1097/00005650-199909000-00002, 10493464.
26. McNamara PS, McCormack P, McDonald AJ, Heaf L, Southern KW. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros 2009, 8:258-263. 10.1016/j.jcf.2009.04.006, 19447080.